The addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients

Nephrology

Volumn 12, Issue SUPPL. 1, 2007, Pages

  Webster, Angela C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CD25 ANTIBODY; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; B CELL ACTIVATING FACTOR; CALCINEURIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TARGETING; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; STANDARD; THROMBOCYTOPENIA; DRUG ANTAGONISM; IMMUNOLOGY; METHODOLOGY; PRACTICE GUIDELINE;

ANTIBODIES; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; CALCINEURIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RECOMBINANT FUSION PROTEINS;

EID: 33846985564     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00732.x     Document Type: Review

References (20)

1. Goebel J, Stevens E, Forrest K et al. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl. Immunol. 2000; 8: 153-9.
2. Cibrik DM, Kaplan B, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. Biodrugs 2001; 15: 655-66.
3. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-91.
4. Pascual J, Marcen R, Ortuno J. Anti-interleukin-2 receptor antibodies: Basiliximab and daclizumab. Nephrol. Dial Transplant. 2001; 16: 1756-60.
5. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Available from URL: http://www.anzdata.org.au/ANZDATA/anzdatawe/come.htm. Accessed February 2003.
6. United Network for Organ Sharing (UNOS). OPTN data. Available from URL: http://www.optn.org. Accessed 25 July 2003.
7. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. 2004; 1: CD003897.
8. Adu D, Cockwell P, Ives NJ et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003; 326: 789-93.
9. Bingyi S, Yeyong Q, Ming C et al. Randomised trial of simulect versus placebo for control of acute rejection in renal allograft recipients. Transplant. Proc. 2003; 35: 192-4.
10. British Renal Association. Treatment of adults and children with renal failure: standards and audit measures (3rd edition). Chapter 8, p. 104. London: Royal College of Physicians of London and the Renal Association, 2002.
11. European best practice guidelines. Nephrol. Dial. Transplant. 2000; 15: 60-63.
12. British Transplant Society. Guidelines relating to solid organ transplants from non-heart beating donors. Available from URL: http://www.bts.org.uk/Forms/GuidelinesNov2004.pdf
13. National Institute for Health & Clinical Excellence - United Kingdom. Immunosuppressive therapy for renal transplantation in adults. NICE Technology Appraisal 85, September 2004. Available from URL: http://www.nice.org.uk/TA085/
14. Keown PA, Balshaw R, Krueger H et al. Economic analysis of basiliximab in renal transplantation. Transplantation 2001; 71: 1573-9.
15. Lorber MI, Fastenau J, Wilson D et al. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin. Transplant. 2000; 14: 479-85.
16. Walters SJ, Whitfield M, Akehurst RL et al. Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant. Proc. 2001; 33: 3187-91.
17. Chilcott JB, Holmes MW, Walters S et al. The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transplant Int. 2002; 15: 486-93.
18. Polsky D, Weinfurt KP, Kaplan B et al. An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. 2001; 16: 1028-33.
19. Lilliu H, Brun-Strang C, Le Pen C et al. Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. Clin. Transplant. 2004; 18: 247-53.
20. Hasegawa T, Imai H, Miki S. Cost evaluation of basiliximab treatment for renal transplant patients in Japan. Pharmacoeconomics 2003; 21: 791-806.